A Phase 1 interventional study of Dexamethasone in Osteoarthritis, Knee, sponsored by Mark Figgie. Completed at 1 site in United States. Open to participants aged 40 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-10-01.
Sponsored by Mark Figgie · Phase 1, Interventional, and Treatment
The purpose of this study is to determine whether a longer duration, controlled, sustained release dexamethasone delivery system would be more effective in helping patients with osteoarthritis reduce their pain, remain functional, and delay their need for knee replacement.
The objectives of the study are to assess the dexamethasone delivery system for:
Formal statistical analysis to compare treatment groups will not be performed due to the small number of participants in this pilot study. Summary statistics will be assessed using the short form of the knee injury and osteoarthritis outcome score (KOOS JR) surveys and questionnaires to assess pain intensity, pain medication consumption and wound assessment.
4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.
This study's enrollment of 6 is below the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.
Browse Osteoarthritis studies →This is the only study on the registry with Mark Figgie as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Dexamethasone
Sustained delivery system containing 5.0 mg of dexamethasone programmed to release an estimated 10 μg per day
Incidence of treatment emergent adverse events
Time frame: Through 24 weeks
Change from baseline in weekly mean of the pain intensity score
Using a numeric rating scale for pain with a scale of 0 (no pain) to 10 (worst pain imaginable) at rest, during activity, and at night
Time frame: Weeks 12, 24
Change from baseline in weekly mean of the pain intensity score
Using a numeric rating scale for pain with a scale of 0 (no pain) to 10 (worst pain imaginable) at rest, during activity, and at night
Time frame: Weekly through 24 weeks
Time of onset of pain relief
Time frame: Weekly through 24 weeks
Change from baseline in KOOS-JR score (stiffness)
Using a response scale of none, mild, moderate, severe, and extreme
Time frame: Over 1, 2, 4, 8, 12, 24 weeks post treatment
Change from baseline in KOOS-JR score (pain)
Using a response scale of none, mild, moderate, severe, and extreme
Time frame: Over 1, 2, 4, 8, 12, 24 weeks post treatment
Change from baseline in KOOS-JR score (function)
Using a response scale of none, mild, moderate, severe, and extreme
Time frame: Over 1, 2, 4, 8, 12, 24 weeks post treatment
Change in patient's global impression of scores assessed via office visits
Using a numeric rating scale for pain with a scale of 0 (no pain) to 10 (worst pain imaginable)
Time frame: Weeks 4, 12, 24
Change in clinical observer's global impression of scores assessed via office visits
Using a numeric rating scale for pain with a scale of 0 (no pain) to 10 (worst pain imaginable)
Time frame: Weeks 4, 12, 24
Percent of responders (defined as patients with high improvement in pain or function) according to OMERACT-OARSI criteria
Time frame: Weeks 1, 2, 4, 8, 12, 24
Average weekly consumption of rescue medications
Time frame: Through 24 weeks
Average total consumption of rescue medications
Time frame: Through 24 weeks
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.